First Trimester Screen | Fß with Instant Risk Assessment from eReports

Only Eurofins NTD, LLC. measures free Beta hCG and acheives: Detection Rate: 91%. False Positive: 5%
for Down syndrome

Early Detection, Early Assurance

First Trimester Screen | Fß with Instant Risk Assessment from eReports enables trained medical professionals to present a complete risk assessment for Down syndrome and trisomy 18 and 13 during a single office visit and ensure same-day results notification for the patient. Performed between 9 weeks and 13 weeks, 6 days of gestation, the Instant Risk Assessment provides a care path for Down syndrome risk assessment that is logistically simple to integrate within your overall prenatal care plan.

In the earlier stages of the pregnancy (9 weeks to 11 weeks, 1 day), a maternal blood sample will be collected and submitted to Eurofins NTD, LLC. where it is processed, tested and archived according to protocol.

The results of the blood screen are maintained at Eurofins NTD, LLC. and made available to the physician when the patient undergoes her NT (and optional fetal nasal bone assessment) ultrasound exam between 11 weeks, 1 day and 13 weeks, 6 days of gestation. To save time, Eurofins NTD, LLC. provides web-based access to your patient's biochemistry data through a secure eReports website. This site provides information management tools that allow you to call up individual patient records, enter key biophysical data from the ultrasound, and then present a complete risk assessment for Down syndrome and trisomy 18 and 13 at the time of the patient's visit. The calculation is based upon your patient's data entered on the spot, so there is less time spent between results reporting and patient notification.

The benefits of the Instant Risk Assessment from eReports Program:

  • Early assurance - since 95% of all pregnant patients are shown to be at low risk, Instant Risk Assessment helps alleviate unnecessary anxiety for the patient and her family by providing early answers in the first trimester.
  • More time to assess options - those women shown to be at increased risk can receive immediate counseling regarding possible follow up diagnostic procedures such as CVS and amniocentesis.

(References 13)

DISCLAIMER: This test is a part of a lab service offering provided by Eurofins NTD, LLC. This test was developed and its performance characteristics determined by Eurofins NTD, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health. The test results do not eliminate the possibility that this pregnancy may be associated with birth defects or pregnancy complications including preeclampsia, pre-term delivery and low birth weight. The multiple of the median and risk results provided in the test report are dependent on the accuracy of the demographic and ultrasound information provided. The ordering physician should ensure that the ultrasound information has been obtained from a sonographer who is credentialed by and participating in a uterine artery Doppler quality review program such as FMF. Eurofins NTD, LLC. assumes no responsibility for ensuring that the ultrasound information has been obtained by a properly credentialed sonographer, including verification or updates to credentialing status.